Cancer Epigenetics and Nanomedicine: Targeting the Right Player via Nanotechnology is a complete package that provides a comprehensive and thorough understanding of the key players that modulate the various steps of carcinogenesis and malignant progression of the disease and the critical targets to be exploited for developing novel modalities of diagnosis and therapeutics. Since epigenetic aberrations can be potentially reversed and restored to their normal state through epigenetic therapy, the book also discusses the challenges and the future of the field with the cutting-edge revelations and limitations that this research endeavor can offer, thereby helping the readers to enhance their critical thinking and adopt strategies of therapeutic importance.
Dr. Prashant Kesharwani is assistant professor of Pharmaceutics at Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, Madhya Pradesh, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 350 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “SERB-Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community. His Number of citations is = 26779; h-index = 85; i-10 index = 370 (According to google scholar on March 2025). He has more than 30 international publications published in very high impact factor journals (Progress in Polymer Sciences IF 32.063, Molecular Sciences IF 41.444, Progress in Material Sciences IF 48.580, Advanced Materials IF 29.4, Drug Resistance Update IF 22.841 and Material Todays IF 32.072). He has presented many invited talks and oral presentations at prestigious scientific peer-conferences, received international acclaims and awards for research contribution, supervised students/junior researchers and actively participated in outreach and scientific dissemination for the service of the wider community.
Dr. Chitra Thakur is an Assistant Professor-Research in the Department of Pathology at the Stony Brook Cancer Center, New York, USA. She is a cancer biologist and has expertise in molecular oncology, mouse models of human cancers, analyzing big data in translational research, toxicology, and epigenetics in human cancers. She is the recipient of several internationally acclaimed awards such as the “DFG German Excellence Initiative Award,”, “NIH-Big Data Training for Translational Omics Research” and “American Cancer Society IRG”. With more than 45 research articles published in mainstream scientific journals, she has contributed significantly towards the understanding of the molecular mechanisms in human cancers. She is engrossed in cancer research, teaching, and community outreach initiatives, hence fostering the scientific community and health care professionals engaged in cancer diagnosis, and treatment.
